Dimension Links With Bayer For Hemophilia | Chemical & Engineering News
Volume 92 Issue 26 | p. 14 | Concentrates
Issue Date: June 30, 2014

Dimension Links With Bayer For Hemophilia

Department: Business
Keywords: gene therapy, hemophilia A, venture capital

Dimension Therapeutics will work with Bayer HealthCare to develop a gene therapy for the treatment of hemophilia A based on Dimension’s adeno-associated virus technology. Dimension says its technology delivers the clotting factor gene, resulting in long-lasting expression of blood-clotting protein. Dimension, based in Cambridge, Mass., will receive $20 million up front from Bayer and could get milestone payments of up to $232 million. Separately, Dimension closed a financing round in which it raised $30 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment